Cargando…
Virtual screening, optimization, and identification of a novel specific PTP-MEG2 Inhibitor with potential therapy for T2DM
Megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) is a tyrosine phosphatase expressed in megakaryocytic cells, and causes insulin sensitization when down regulated. Therefore, specific inhibitors of PTP-MEG2 are potential candidates for novel Type 2 Diabetes (T2DM)therapy. In this study, we di...
Autores principales: | Wang, Meiyan, Li, Xiaobo, Dong, Lei, Chen, Xiubo, Xu, Weiren, Wang, Runling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239439/ https://www.ncbi.nlm.nih.gov/pubmed/27384997 http://dx.doi.org/10.18632/oncotarget.10341 |
Ejemplares similares
-
Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM
por: Spazzafumo, Liana, et al.
Publicado: (2017) -
COX-2 metabolic products, the prostaglandin I(2) and F(2α), mediate the effects of TNF-α and Zn(2+) in stimulating the phosphorylation of Tau
por: Wang, Yue, et al.
Publicado: (2017) -
Novel inhibitor candidates of TRPV2 prevent damage of dystrophic myocytes and ameliorate against dilated cardiomyopathy in a hamster model
por: Iwata, Yuko, et al.
Publicado: (2018) -
MeCP2 mediated dysfunction in senescent EPCs
por: Wang, Chunli, et al.
Publicado: (2017) -
DNA damage response (DDR) and senescence: shuttled inflamma-miRNAs on the stage of inflamm-aging
por: Olivieri, Fabiola, et al.
Publicado: (2015)